MyMedR

Fulltext Allergic skin tests in Malaysian asthmatics

Ismail Y

Med J Malaysia, 1992 Mar;47(1):69-73.

To assess the prevalence of skin test sensitivity among asthmatic patients in Malaysia, skin prick tests for allergy in 134 adult asthmatic patients and 120 control subjects were done. 90% of asthmatic patients had positive skin test to at least one allergens as compared to 78% of the controls. House dust mite was the most frequent allergen to which the subjects had positive reactions. Sixty-four percent of the asthmatic patients had associated rhinitis. There was no significant difference in the skin test sensitivity between asthmatic patients with associated rhinitis and those without.

Matched MeSH terms: Asthma/immunology*

Experience with skin reactions to various allergens in bronchial asthma

Zulkifli A, Weng CK

Med J Malaysia, 1979 Dec;34(2):153-5.

PMID: 548718

Matched MeSH terms: Asthma/immunology*

Novel Biologicals for the Treatment of Allergic Diseases and Asthma

Tan HT, Sugita K, Akdis CA

Curr Allergy Asthma Rep, 2016 10;16(10):70.

PMID: 27613653 DOI: 10.1007/s11882-016-0650-5

PURPOSE OF REVIEW: The development of biological therapies has rapidly progressed during the last few years, and major advances were reported for the treatment of allergic diseases, such as atopic dermatitis, allergic rhinitis, urticaria, food allergy, and asthma. Here, we review biologicals targeting the type 2 immune response involving Th2 cells, type 2 innate lymphoid cells, natural killer T cells, mast cells, basophils, and epithelial cells, such as IL-4, IL-5, IL-13, IL-31, tumor necrosis factor alpha (TNF-α), and thymic stromal lymphopoietin (TSLP).

RECENT FINDINGS: The biologicals that have been currently approved for asthma are omalizumab targeting IgE and reslizumab and mepolizumab targeting interleukin (IL)-5. Many other monoclonal antibodies are currently in various phases of clinical development. The new biological therapies for allergic diseases will eventually be tailored to the endotypes of these diseases and the identification of novel biomarkers. Further development of novel biologicals for the treatment of allergic diseases and asthma will be possible upon improved understanding of mechanisms of allergic diseases. Accordingly, further refinement of endotypes of allergen-specific and non-specific type 2 immune response and related inflammatory mediators is needed for optimal treatment of allergic diseases.

Matched MeSH terms: Asthma/immunology*

Ige, parasites, and allergy

Kok A, Robinson MJ

Lancet, 1976 Sep 18;2(7986):633.

PMID: 61371

Matched MeSH terms: Asthma/immunology

Displaying publications 21 - 24 of 24 in total